Old drugs are often repurposed, or re-entered
into the pharmaceutical market, for their potential to treat medical afflictions
in a new way. With Belcher Pharmaceuticals and their recent actions concerning
Ablysinol, a dehydrated alcohol solution used in certain heart procedures, this
is not the case.
In a statement on
BioSciences CEO Douglas Williams and seven other biotech CEOs singled
out Seminole, Florida-based Belcher Pharmaceuticals, based on the Food and Drug
Administration approval earlier this month of Ablysinol (dehydrated alcohol),
an old drug used in certain heart procedures. The company received the approval
not by conducting clinical trials on its own, but through a pathway known as
505(b)(2), whereby it was based on a review of data from 38 publications by
A Price Increase of Nearly $9,000
Belcher’s executives claimed to have invested multiple millions of dollars into
Ablysinol’s approval, the pathway they took was relatively cheaper than it
would have been if they had discovered and developed the drug on their own.
Nevertheless, as reported by
STAT, the company received seven years of mar...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).